What non-taxane chemotherapy, if any, would you give with trastuzumab in adjuvant setting of a pT1cN0 HER2+ breast CA in patients with hyperbilirubinemia >3 due to cirrhosis?

In this difficult case, the risks of any therapy may outweigh the benefits. Depending on the patient's age, etiology of the cirrhosis, and eligibility for liver transplant, I might think about single-agent trastuzumab.